medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2018, Number 3

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2018; 16 (3)

Vascular Endotelial Growth Factor and Ki-67 Proliferation Index in Nodular Melanoma

Chinchilla-Castañeda K, Mercadillo-Pérez P

Language: Spanish
References: 21
Page: 192-198
PDF size: 191.18 Kb.


ABSTRACT

Background: melanoma is the less common form of skin cancer, but causes over 75% of deaths from skin cancers worldwide. In Mexico, the overall incidence of melanoma calculated is 1.01/100 000. Nodular melanoma is the first or second most common, after acral lentiginous melanoma. This subtype is known for his aggressive behavior, metastasic probability, as well as its poor prognosis. Lymphangiogenesis has been linked to higher incidence of metastases in sentinel node and a lower survival free disease. This parameter is facilitated by the production of VEGF among other factors.
Objective: measure the expression of vascular endothelial growth factor and proliferative index Ki-67 in nodular melanoma at the Dermatopathology Service of the General Hospital of Mexico, from January 2010 to December 2014.
Methodology: cross-sectional descriptive study. A semiquantitative measure of VEGF expression and proliferative index Ki-67 was conducted in 51 cases of nodular melanoma. Statistical methods were performed between the two markers.
Results: when using Pearson’s statistical method the correlation between the expression of VEGF and Ki-67 proliferative index was statistically significant (P ‹ 0.006).
Conclusions: these findings let us know that the higher the expression of vascular endothelial growth, the higher the ability to facilitate cell replication, which could have a major impact on tumorigenesis pathways.


REFERENCES

  1. NCI Cancer Net Database, disponible en: http://www.cancer.gov/espanol/ tipos/melanoma. Consultado: 14 de noviembre de 2014.

  2. National Cancer Institute, Surveillance, epidemiology and end results. Disponible en: http://www.seer.cancer.gov/statfacts. Consultado: 14 de noviembre de 2014.

  3. International Agency for Research on Cancer, Globocan 2002. Disponible en: http://www-dep.iarc.fr/. Consultado: 14 de noviembre de 2014.

  4. Gutiérrez R y Cortés N, Confrontando al melanoma en el siglo xxi, Med Cutan Iber Lat Am 2007; 35(1):3-13.

  5. Eran H, Watson IR, Kryukov GV et al., A landscape of driver mutations in melanoma, Cell 2012; 159(2): 251-63.

  6. Gandini S, Sera F, Cattaruzza M et al., Meta-analysis of risk factors for cutaneous melanoma: iii. Family history, actinic damage and phenotypic factors, Eur J Cancer 2005; 41: 2040-59.

  7. Tsao H, Chin L, Garraway L et al., Melanoma: from mutations to medicine, Genes Dev 2012; 26:1131-55.

  8. Van Leeuwen MT, Webster AC, McCredie MR et al., Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study, BMJ 2010; 340(570):1-6.

  9. Alfeirán-Ruiz A, Escobar G, Barreda F et al., Epidemiología del melanoma de piel en México, Rev Ins Nal Cancerol 1998; 44(4): 168-74.

  10. Saucedo A, Gutiérrez R y Medina A, Cáncer de piel en el Centro Dermatológico Pascua. Estudio epidemiológico de 10 años, Dermatología Rev Mex 2005; 49(6): 231-9.

  11. Orendain-Koch N, Ramos-Álvarez M y Ruiz-Leal A, Melanoma en la práctica privada en México: un diagnóstico oportuno, Dermatol Rev Mex 2015; 59:89-97.

  12. Egger M, Dunki-Jacobs EM, Callender GG et al., Outcomes and prognostic factors in nodular melanomas, Surgery 2012; 152:652-60.

  13. Eggermont AM, Spatz A. y Robert C, Cutaneous melanoma, The Lancet 2014; 383(9919):816-27.

  14. Tejera-Vaquerizo A, Solís-García E, Ríos-Martín J et al., Factores pronósticos en el melanoma cutáneo primario no incluidos en la clasificación de la American Joint Committee on Cancer (ajcc), Actas Dermosifiliogr 2011; 102(4):255-63.

  15. Ladstein RG, Bachmann IM, Straume O et al., Ki-67 expression is superior to mitotic count and novel proliferation markers phh3, mcm4 and mitosin as a prognostic factor in thick cutaneous melanoma, bmc Cancer 2010; 10(140):1-15.

  16. Káram-Orantes M, Toussaint-Caire S, Domínguez-Cheritc J et al., Características clínicas e histopatológicas del melanoma maligno en el Hospital General “Dr. Manuel Gea González”, Gac Méd Méx 2008; 144(3):219-23.

  17. Bevona C y Sober AJ, Melanoma incidence trends, Dermatol Clin 2002; 20:589-95.

  18. Haydu LE, Murali R, Bonenkamp JJ et al., Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma, Ann Surg 2012; 255:1165-70.

  19. Konstantina A, Lazaris AC, Ioannidis E et al., Immunohistochemical expression of vegf, hif1-a, and plgf in malignant melanomas and dysplastic nevi, Melanoma Res 2011; 21:389-94.

  20. Dadras SS, Lange-Asschenfeldt B, Velasco P et al., Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes, Mod Pathol 2005; 18:1231-42.

  21. Ben-Izhak O, Bar-Chana M, Sussman L et al., Ki-67 antigen and pcna proliferation markers predict survival in anorectal malignant melanoma, Histopathology 2002; 41:519-25.




2020     |     www.medigraphic.com